3-Aminobenzamide (PARP-IN-1) (>1 μM) causes more than 95% inhibition of PARP activity without significant cellular toxicity. INO-1001 significantly sensitizes CHO cells by blocking most of the DNA repair occurring between radiation fractions. 3-Aminobenzamide significantly improves endothelial function by enhancing the acetylcholine-induced, endothelium-dependent, nitric oxide mediated vasorelaxation after exposure with 400 μM H ₂ O ₂ .

In a db/db (Lepr db/db ) mouse model, 3-Aminobenzamide ameliorates diabetes-induced albumin excretion and mesangial expansion, and also decreases diabetes-induced podocyte depletion. 3-Aminobenzamide (1.6 mg/kg via intracerebral injection) prevents NAD ⁺ depletion and improves water maze performance after controlled cortical impact (CCI) in mice.